跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT
Hsin Hsien Yeh
, Kazuma Ogawa
, Julius Balatoni
, Uday Mukhapadhyay
, Asutosh Pal
, Carlos Gonzalez-Lepera
, Aleksandr Shavrin
, Suren Soghomonyan
, Leo Flores
, Daniel Young
, Andrei Y. Volgin
, Amer M. Najjar
, Victor Krasnykh
, William Tong
, Mian M. Alauddin
, Juri G. Gelovani
腦科學研究中心
研究成果
:
Article
›
同行評審
88
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Phosphotransferase
100%
Molecular Imaging
100%
Positron Emission Tomography-Computed Tomography
100%
Fluorine-18
50%
Xenograft
30%
Gefitinib
30%
Polyethylene Terephthalate
20%
Gene Sequence
10%
Neoplasm
10%
Biological Marker
10%
Signal Transduction
10%
Personalized Medicine
10%
Quinazoline
10%
Diagnostic Imaging
10%
Erlotinib
10%
Phosphotransferase Inhibitor
10%
Radioactive Tracer
10%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Therapeutic Agent
10%
Tumor
10%
Acrylamide
10%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Phosphotransferase
100%
Epidermal Growth Factor Receptor
100%
Polyethylene Terephthalate
100%
Fluorine 18
50%
Gefitinib
30%
Neoplasm
10%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Biological Marker
10%
Quinazoline
10%
Phosphotransferase Inhibitor
10%
Erlotinib
10%
Tracer
10%
Acrylamide
10%
Neuroscience
Molecular Imaging
100%
Kinase
100%
Epidermal Growth Factor Receptor
100%
Positron Emission Tomography-Computed Tomography
100%
Fluorine-18
45%
Positron Emission Tomography
18%
Gefitinib
18%
Cell Signaling
9%
Gene Sequence
9%
Quinazoline
9%
Biological Marker
9%
Acrylamide
9%
Personalized Medicine
9%
Keyphrases
Irreversible Binding
22%
EGF Receptor Inhibitor
11%
Dual mutations
11%
Individualized Therapy
11%